Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.
Dendritic cells (DCs) are professional antigen-presenting cells playing a pivotal role in the induction of humoral and cellular immune responses, and chronic myeloid leukemia-derived DCs (CML-DCs) are possible candidates for inducing anti-leukemic immunity. This review describes phenotypic and functional features of DCs derived from CML patients as compared with DCs from healthy volunteers. In short, distinct deficiencies have been reported for CML-DCs, such as reduced migration, endocytosis, phagocytosis, antigen processing, DC maturation and cytokine production. DC abnormalities of CML patients can be abrogated by proper in vitro stimulation of leukemic DCs. This underscores the importance of proper generation and maturation of CML-DCs when considering clinical vaccination protocols.
Eisendle
Klaus
K
Laboratory for Tumor and Immunobiology, Division of Hematology and Oncology, Innsbruck Medical University, Innsbruck, Austria. klaus.eisendle@uibk.ac.at
Wolf
Dominik
D
Gastl
Guenther
G
Kircher-Eibl
Brigitte
B
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D019496:Cancer Vaccines / Q000627:therapeutic use; D016207:Cytokines / Q000096:biosynthesis; D003713:Dendritic Cells / Q000187:drug effects / Q000276:immunology*; D016044:Fusion Proteins, bcr-abl / Q000276:immunology; D006801:Humans; D000068877:Imatinib Mesylate; D016130:Immunophenotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000628:therapy; D008213:Lymphocyte Activation; D022423:Myeloid Cells / Q000276:immunology; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D000970:Antineoplastic Agents; D001549:Benzamides; D019496:Cancer Vaccines; D016207:Cytokines; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl